Iovance Biotherapeutics, Inc. Common Stock (IOVA) Technical Analysis
$10.19
Market is closed - opens 7 PM, 22 Sep 2026
Insights
- Iovance Biotherapeutics Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Iovance Biotherapeutics Inc. stock suggests that it is a good time to sell or bad time to initiate a fresh position
- Based on analysis of the Moving Averages technical indicator, Iovance Biotherapeutics Inc. stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Iovance Biotherapeutics Inc. stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 74.35 | Sell |
Stochastic | 73.75, 74.28 | Neutral |
Ultimate Oscillator | 53.49 | Neutral |
Stochastic Relative Strength Index | 97.72, 98.97 | Sell |
Moving Average Convergence Divergence | 0.86, 0.79 | Buy |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 9.28 | Buy |
20 | 8.81 | Buy |
50 | 6.91 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 9.48 | Buy |
20 | 8.83 | Buy |
50 | 7.37 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 9.44 | Buy |
20 | 8.98 | Buy |
50 | 6.81 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 10.13 | Buy |
20 | 9.98 | Buy |
50 | 9.19 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 10.26 | Buy |
20 | 10.11 | Buy |
50 | 9.96 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 10.84 |
Resistance L2 | 10.56 |
Resistance L1 | 10.4 |
Pivot Point | 10.12 |
Support L1 | 9.96 |
Support L2 | 9.68 |
Support L3 | 9.52 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.